The soluble isoform of the interferon-β (IFN-β) receptor (sIFNAR2) could modulate the activity of both endogenous and systemically administered IFN-β. Previously, we described lower serum sIFNAR2 levels in untreated multiple sclerosis (MS) than in healthy controls (HCs).
Objective:
To assess sIFNAR2 levels in a new cohort of MS patients and HCs, as well as in patients with clinically isolated syndrome (CIS) and with other inflammatory neurological disorders (OIND) and to assess its ability as a diagnostic biomarker.
Methods:
The cross-sectional study included 148 MS (84 treatment naive and 64 treated), 87 CIS, 42 OIND, and 96 HCs. Longitudinal study included 94 MS pretreatment and after 1 year of therapy with IFN-β, glatiramer acetate (GA), or natalizumab. sIFNAR2 serum levels were measured by a quantitative ELISA developed and validated in our laboratory.
Results:
Naive MS and CIS patients showed significantly lower sIFNAR2 levels than HCs and OIND patients. The sensitivity and specificity to discriminate between MS and OIND, for a sIFNAR2 cutoff value of 122.02 ng/mL, were 70.1%, and 79.4%, respectively. sIFNAR2 increased significantly in IFN-β-treated patients during the first year of therapy in contrast to GA- and natalizumab-treated patients who showed non-significant changes.
Conclusion:
The results suggest that sIFNAR2 could be a potential diagnostic biomarker for MS.
SeveraMRizzoFGiacominiE. IFN-β and multiple sclerosis: Cross-talking of immune cells and integration of immunoregulatory networks. Cytokine Growth Factor Rev2015; 26(2): 229–239.
3.
UzéGSchreiberGPiehlerJ. The receptor of the type I interferon family. Curr Top Microbiol Immunol2007; 316: 17–95.
4.
StarkGRKerrIMWilliamsBR. How cells respond to interferons. Annu Rev Biochem1998: 67: 227–264.
5.
Fernandez-BotranRChiltonPMMaY. Soluble cytokine receptors: Their roles in immunoregulation, disease, and therapy. Adv Immunol1996; 63: 269–336.
6.
MaYHurstHEFernandez-BotranR. Soluble cytokine receptors as carrier proteins: Effects of soluble interleukin-4 receptors on the pharmacokinetics of murine interleukin-4. J Pharmacol Exp Ther1996: 279: 340–350.
7.
AderkaDEngelmannHMaorY. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med1992; 175(2): 323–329.
8.
Peleg-ShulmanTRoismanLCZupkovitzG. Optimizing the binding affinity of a carrier protein: A case study on the interaction between soluble IFNAR2 and interferon beta. J Biol Chem2004; 279(17): 18046–18053.
9.
KondoNKondoSShimizuA. A soluble “anchorminus” interleukin 2 receptor suppresses in vitro interleukin 2-mediated immune responses. Immunol Lett1988; 19: 299–307.
10.
WolfJRose-John SandGarbersC. Interleukin-6 and its receptors: A highly regulated and dynamic system. Cytokine2014; 70: 11–20.
11.
OwczarekCMHwangSYHollandKA. Cloning and characterization of soluble and transmembrane isoforms of a novel component of the murine type I interferon receptor, IFNAR 2. J Biol Chem1997; 272(38): 23865–23870.
12.
DomanskiPWitteMKellumM. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J Biol Chem1995; 270(37): 21606–21611.
13.
NovickDCohenBTalN. Soluble and membrane-anchored forms of the human IFN-alpha/beta receptor. J Leukoc Biol1995; 57(5): 712–718.
14.
NovickDCohenBRubinsteinM. Soluble interferon-alpha receptor molecules are present in body fluids. FEBS Lett1992; 14(3): 445–448.
15.
HardyMPOwczarekCMTrajanovskaS. The soluble murine type I interferon receptor IFNAR-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood2001; 97(2): 473–482.
16.
JaksEGavutisMUzéG. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol2007; 366(2): 525–539.
17.
McKennaSDVergilisKArulanandamAR. Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice. J Interferon Cytokine Res2004; 24(2): 119–129.
Oliver-MartosBOrpezTPinto-MedelMJ. Gene expression in IFNβ signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patients. J Neuroimmunol2011; 230(1–2): 153–159.
20.
ComabellaMLunemannJDRioJ. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain2009; 132(Pt 12): 3353–3365.
21.
GilliFValentinoPCaldanoM. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. Neurology2008; 71: 1940–1947.
22.
Órpez-ZafraTPavķaJPinto-MedelMJ. Development and validation of an ELISA for quantification of soluble IFN-β receptor: Assessment in multiple sclerosis. Bioanalysis2015; 7: 2869–2880.
23.
PolmanCHReingoldSCBanwellB. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69: 292–302.
24.
ValentinMAMaSZhaoA. Validation of immunoassay for protein biomarkers: Bioanalytical study plan implementation to support pre-clinical and clinical studies. J Pharm Biomed Anal2011; 55(5): 869–877.
25.
LundströmWHighfillSWalshST. Soluble IL7Ra potentiates IL-7 bioactivity and promotes autoimmunity. Proc Natl Acad Sci U S A2013; 110: E1761–E1770.
MizukoshiEKanekoSKajiK. Serum levels of soluble interferon Alfa/Beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C. Hepatology1999; 30(5): 1325–1331.
28.
AmbrusJLAmbrusJLJChadhaS. Mechanism(S) of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis. Res Commun Mol Pathol Pharmacol1997; 96(3): 255–265.
29.
SamarajiwaSAManganNEHardyMP. Soluble IFN receptor potentiates in vivo type I IFN signaling and exacerbates TLR4-mediated septic shock. J Immunol2014; 192(9): 4425–4435.
30.
AmbrusJLSDembinskiWAmbrusJLJ. Free interferon-alpha/beta receptors in the circulation of patients with adenocarcinoma. Cancer2003; 98(12): 2730–2733.
31.
MiyakeKImuraSNishiokaM. Serum evaluation of soluble interferon-alpha/beta receptor and high-sensitivity C-reactive protein for diagnosis of the patients with gastrointestinal and hepatobiliary-pancreatic cancer. Cytokine2010; 49: 251–255.
32.
ChadhaKWeinstock-GuttmanBZivadinovR. Interferon inhibitory activity in patients with multiple sclerosis. Arch Neurol2006; 63(11): 1579–1584.
33.
PioliPDSalehAMEl FikyA. Sequential proteolytic processing of an interferon-alpha receptor subunit by TNF-alpha converting enzyme and presenilins. J Interferon Cytokine Res2012; 32(7): 312–325.
34.
KaplanBAizenbudBMGoldermanS. Free light chain monomers in the diagnosis of multiple sclerosis. J Neuroimmunol2010; 229: 263–271.
35.
ComabellaMFernándezMMartinR. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain2010; 133(Pt 4): 1082–1093.
